The NFKB1 -94 ATTG insertion/deletion polymorphism (rs28362491) contributes to the susceptibility of congenital heart disease in a Chinese population

Gene

Volumn 516, Issue 2, 2013, Pages 307-310

  Zhang, Danyan ^a,b   Li, Lianbing ^a,b   Zhu, Yijian ^a,b   Zhao, Letian ^a,b   Wan, Ling ^a,b   Lv, Jing ^a,b   Li, Xinsheng ^a,b   Huang, Pei ^c   Wei, Li ^a,b   Ma, Mingfu ^a,b  

^a Chongqing Key Laboratory of Birth Defects and Reproductive Health   (China)

^b Chongqing Institute of Population and Family Planning   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Congenital heart disease (CHD); NFKB1; Polymorphism; Risk; Rs28362491

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CHINESE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOTYPE; HEART DEFECTS, CONGENITAL; HUMANS; INDEL MUTATION; INFANT; INFANT, NEWBORN; MALE; NF-KAPPA B P50 SUBUNIT;

EID: 84873253313     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.12.078     Document Type: Article

References (30)

1. Baeuerle P.A., Baltimore D. NF-kappa B: ten years after. Cell 1996, 87:13-20.
2. Bentham J., Bhattacharya S. Genetic mechanisms controlling cardiovascular development. Ann. N. Y. Acad. Sci. 2008, 1123:10-19.
3. Bruneau B.G. The developmental genetics of congenital heart disease. Nature 2008, 451:943-948.
4. Buckingham M., Meilhac S., Zaffran S. Building the mammalian heart from two sources of myocardial cells. Nat. Rev. Genet. 2005, 6:826-835.
5. Chen F., Castranova V., Shi X., Demers L.M. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem. 1999, 45:7-17.
6. Clark K.L., Yutzey K.E., Benson D.W. Transcription factors and congenital heart defects. Annu. Rev. Physiol. 2006, 68:97-121.
7. Demaria S., et al. Cancer and inflammation: promise for biologic therapy. J. Immunother. 2010, 33:335-351.
8. Dhingra R., Shaw J.A., Aviv Y., Kirshenbaum L.A. Dichotomous actions of NF-kappaB signaling pathways in heart. J. Cardiovasc. Transl. Res. 2010, 3:344-354.
9. Gao M., Wang C.H., Sima X., Han X.M. NFKB1-94 insertion/deletion ATTG polymorphism contributes to risk of systemic lupus erythematosus. DNA Cell Biol. 2012, 31:611-615.
10. Hernandez-Gutierrez S., et al. NF-kappaB signaling blockade by Bay 11-7085 during early cardiac morphogenesis induces alterations of the outflow tract in chicken heart. Apoptosis 2006, 11:1101-1109.
11. Hoffman J.I. Incidence of congenital heart disease: II. Prenatal incidence. Pediatr. Cardiol. 1995, 16:155-165.
12. Hoffman J.I., Kaplan S. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 2002, 39:1890-1900.
13. Huang J.B., Liu Y.L., Sun P.W., Lv X.D., Du M., Fan X.M. Molecular mechanisms of congenital heart disease. Cardiovasc. Pathol. 2010, 19:e183-e193.
14. Jenkins K.J., et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007, 115:2995-3014.
15. Jones W.K., Brown M., Ren X., He S., McGuinness M. NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling?. Cardiovasc. Toxicol. 2003, 3:229-254.
16. Karban A.S., et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum. Mol. Genet. 2004, 13:35-45.
17. Li Q.Y., et al. Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Nat. Genet. 1997, 15:21-29.
18. Lopez-Mejias R., et al. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2012, 224:426-429.
19. Mou S.S., et al. Myocardial inflammatory activation in children with congenital heart disease. Crit. Care Med. 2002, 30:827-832.
20. Pierpont M.E., et al. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007, 115:3015-3038.
21. Qing M., et al. Intramyocardial synthesis of pro- and anti-inflammatory cytokines in infants with congenital cardiac defects. J. Am. Coll. Cardiol. 2003, 41:2266-2274.
22. Schott J.J., et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 1998, 281:108-111.
23. Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986, 46:705-716.
24. Srivastava D. Making or breaking the heart: from lineage determination to morphogenesis. Cell 2006, 126:1037-1048.
25. Valen G., Yan Z.Q., Hansson G.K. Nuclear factor kappa-B and the heart. J. Am. Coll. Cardiol. 2001, 38:307-314.
26. Van der Heiden K., Cuhlmann S., Luong le A., Zakkar M., Evans P.C. Role of nuclear factor kappaB in cardiovascular health and disease. Clin. Sci. (Lond.) 2010, 118:593-605.
27. Wang X., et al. Updated meta-analysis of NFkappaB1 -94ins/Delattg promoter polymorphism and cancer risk based on 19 case-control studies. Asian Pac. J. Cancer Prev. 2011, 12:2479-2484.
28. Zhou B., et al. Functional polymorphism of the NFKB1 gene promoter is related to the risk of dilated cardiomyopathy. BMC Med. Genet. 2009, 10:1-5.
29. Zhou B., et al. A functional promoter polymorphism in NFKB1 increases susceptibility to endometriosis. DNA Cell Biol. 2010, 29:235-239.
30. Zou Y.F., et al. Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis. Cancer Invest. 2011, 29:78-85.